Medron Medical Systems Inc. is Introducing MVision’s Groundbreaking Auto-Segmentation Solution to Canada

Helsinki – December 9, 2021 – MVision AI, the leading software service provider of guideline-based AI segmentation, GBAIS™, for radiotherapy treatment planning, declares a new distribution partnership with Medron Medical Systems, Canada’s choice health equipment provider (subject to approval from Health Canada).

The collaboration authorizes Medron Medical Systems to distribute products and services of MVision AI throughout Canada. Medron Medical Systems and MVision AI are devoted to helping oncology departments receive exceptional and consistent radiotherapy machine learning solutions across Canada. MVision AI’s specialists will be collaborating with Medron Medical System Inc.’s experts to undertake the distribution of the finest, most convenient, and consistent radiotherapy services. 

“Innovation and the introduction of new modalities in radiation oncology have changed the landscape in how radiation therapy is delivered. The introduction of artificial intelligence (AI) in treatment planning is the beginning of a new era that will ultimately lead to greater accuracy in radiation dose delivery, leading to improved patient outcomes,” said Ronald Wallace, President of Medron Medical Systems Inc. 

“Medron Medical Systems Inc. is proud to partner with MVision in developing the Canadian market of their Automatic Segmentation platform using their unique AI algorithms.”

As stated by MVision AI’s CEO and Co-Founder, Mahmudul Hasan, “MVision is continuing its rapid expansion. We are excited to start this partnership with Medron Medical Systems Inc. for Canadian hospitals. We are well ahead of our mission to serve radiotherapy patients with fast and high-quality treatment plans.” 

For additional inquiries on Medron Medical System:

Medron Medical System

Website: https://www.medron.ca/

Email: info@medron.ca

Tel: +1 613-769-3302 

MVision AI is active on LinkedInTwitterFacebook, and Instagram. Follow us on social media and subscribe to our newsletter to stay up-to-date on the latest MVision AI news.

Are you eager to learn more about GBAIS™? We welcome you to contact MVision AI:

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@ mvision.ai 

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

19.2.2024

MVision AI is delighted to announce that we have received our 2nd order for the Republic of Ireland from St. Luke’s Radiation Oncology Network (SLRON)

Finland, Helsinki, February 19, 2024 The contract for installing Contour+ Guideline Based AI Segmentation tool has been won through the public tender process and implies a three-year agreement for 5,000 scans per year. This order comes in quick succession following MVision AI's successful award of the tender from the Republic…

Press Releases

14.2.2024

New proofs supporting the efficacy of radiation therapy for kidney cancer 

February is the month when Cancer research UK raises awareness about kidney cancer. In 2020 over 400 000 people were diagnosed with this disease, and almost 180 000 died, worldwide. In the UK, there are over 13 000 new cases each year, on average, and almost 5000 lost lives. The…

Articles

2.2.2024

World Cancer Day – Joining efforts for a better cancer care

World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International Cancer Control (UICC) , the oldest and largest global membership organization dedicated to taking action on cancer. UICC has over 1150 member organizations in 172…

News